Indian Journal of Urology Users online:765  
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size

Year : 2009  |  Volume : 25  |  Issue : 3  |  Page : 421-423

Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasia

Department of Urology, PGIMER, Chandigarh, India

Date of Web Publication1-Oct-2009

Correspondence Address:
S K Singh
Department of Urology, PGIMER, Chandigarh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions


How to cite this article:
Agrawal S K, Agarwal M M, Singh S K. Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasia. Indian J Urol 2009;25:421-3

How to cite this URL:
Agrawal S K, Agarwal M M, Singh S K. Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasia. Indian J Urol [serial online] 2009 [cited 2023 Feb 5];25:421-3. Available from:

Brisinda G, Cadeddu F,Vanella S, Mazzeo P, Marniga G, Maria G. Relief by Botulinum Toxin of Lower Urinary Tract Symptoms Owing to Benign Prostatic Hyperplasia: Early and Long-Term Results. Urology 2009;73:90-4.

   Summary Top

In this open-labeled study, 77 men with BPH received an intraprostatic injection of 200 units of Botulinum toxin A (BT-A, Botox) using an ultrasound-guided transperineal approach. The American Urological Association (AUA) score, serum prostate-specific antigen (PSA), prostatic volume, residual volume, and peak urinary flow rates were evaluated before and after treatment at 1, 2, 6, 12, 18, 24, and 30 months follow-up. The primary endpoint was symptomatic improvement (AUA score) and peak urinary flow rates. The secondary endpoint was the evaluation of prostatic volume, serum PSA, and residual urinary volume.

At an evaluation after 1 month, 41 patients had subjective symptomatic relief. Compared with baseline values, the AUA score was reduced from 24.1 ± 4.6 to 12.6 ± 2.9 (P = 0.00001) and serum PSA was reduced from 6.2 ± 1.7 to 4.8 ± 1.0 ng/mL (P = 0.03). At the same time, the prostatic volume and residual urine volume were reduced by 12.7% and 12.8%, respectively and the mean peak urinary flow rate increased from 8.6 ± 2.9 to 13.1 ± 4.0 (P = 0.01). At an evaluation after 2 months, 55 patients had subjective symptomatic relief. The AUA score was reduced by 63.9% (P = 0.00001) compared with baseline values. In the same patients, serum PSA, prostatic volume, and residual urine volume were reduced by 51.6% (P = 0.00001), 42.8% (P = 0.00001), and 55.9% (P = 0.002), respectively and the mean peak urinary flow rate increased significantly. No local or systemic complications were observed after the treatment and none of the patients required narcotic analgesia after the procedure.

At the evaluation after 30 months, all 77 patients continued to have good voiding without worsening of LUTS. Their AUA symptoms score was 11.1 ± 2.7 (P = 0.02 vs. 2-month value) and total PSA was 3.1 ± 0.7 ng/mL (P = 0.7 vs. 2-month value).

Authors concluded that intraprostatic Botulinum toxin injection is a promising approach that is safe and effective.

   Comment Top

Recently, there have been many reports of use of BT-A in cases of symptomatic BPH. [1],[2],[3] It has been reported to induce apoptosis of prostatic stromal as well as epithelial cells and to decrease smooth muscle contractility. [3],[4] Therefore, intraprostatic BT-A injection is likely to be effective in patients with BPH including those with a small prostate. [2]

Maria, et al. [1] pioneered the use of BT-A intraprostatic injections in patients with BPH. They reported a 50% decrease in prostate volume and significant symptomatic improvement in 13 out of 15 patients. Based on the present study, it appears that all patients with BPH are candidates for intraprostatic BT-A injection. The patient who doesn't receive any benefits with the first injection is likely to receive benefits with repeat injection. Significant improvements in subjective and objective parameters were observed in all 77 patients sooner or later. Although reinjection was required in 22, 14, and 7 patients at 2, 6, and 24 months of follow-up, improvement was seen in all the parameters after reinjection.

Minimally invasive options like TUMT, TUNA, etc. are usually offered to those with high risk for surgery; however these procedures have their own limitations. The BT-A therapy appears to be an attractive option even in high-risk patients with indwelling catheters or severe LUTS refractory to medical treatment. Recently Silva, et al. [5] reported that catheter removal was possible in 17 out of 21 patients of refractory urinary retention who were high-risk or had advanced malignancy.

Although it is too early to this about the use of BT-A in normal risk patients, it seems logical. Medical therapies used today for treatment of BPH are costly, have side effects, and require the patient's compliance, whereas treatment with BT-A doesn't require compliance and its effect may last for more than 2 years, as reported in this study. Moreover, this therapy seems to be free of complications and can be offered as an office procedure. Like the other studies, reduction in prostate size up to 50% was seen in this study. Long-term benefits may be due to reduction in prostate size after BT-A injection.

Results from this and other studies [ 1],[2][3],[5] show that intraprostatic BT-A injection has a place in the treatment of symptomatic patients with BPH and it seems to be safe, effective, and durable. However, more trials and studies compared with other modalities of treatments are required to arrive at a definite conclusion. The cost of BT-A treatment and the availability of ultrasound and expertise will be a limiting factor in our country.

   References Top

1.Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by Botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003;62:259-64.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]  
2.Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB. Botulinum toxin type a improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005;66:775-9.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]  
3.Chuang YC, Chancellor MB. The application of botulinum toxin in the prostate. J Urol 2006;176:2375-82.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]  
4.Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. Botox-induced prostatic involution. Prostate 1998;37:44-50   Back to cited text no. 4  [PUBMED]  [FULLTEXT]  
5.Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P, et al. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement: effect on prostate volume and micturition resumption. Eur Urol 2008;53:153-9.  Back to cited text no. 5  [PUBMED]  [FULLTEXT]  

This article has been cited by
1 The use of botulinum toxin in benign prostatic hyperplasia
Marchal, C. and Perez, J.E. and Herrera, B. and MacHuca, F.J. and Redondo, M.
Neurourology and Urodynamics. 2012; 31(1): 86-92
2 Thermology 2009 - A computer- assisted literature survey
Ammer, K.
Thermology International. 2010; 20(1): 5-27


Print this article  Email this article
Previous article Next article


   Next article
   Previous article 
   Table of Contents
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (78 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


 Article Access Statistics
    PDF Downloaded219    
    Comments [Add]    
    Cited by others 2    

Recommend this journal